Chen Rong, Dong Lei, Wei Tianci, Wang Qiang
Department of Graduate, Hebei North University, Zhangjiakou, China.
Department of Urology, Peking University People's Hospital, Beijing, China.
Transl Androl Urol. 2025 May 30;14(5):1214-1229. doi: 10.21037/tau-2024-728. Epub 2025 May 27.
Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive renal malignancy. Migrasomes, newly discovered organelles involved in intercellular communication, and long non-coding RNAs (lncRNAs) are emerging regulators of cancer progression. However, the role of migrasome-associated lncRNAs in ccRCC prognosis and immune response remains unclear. This study aimed to investigate the value of migrasome-related lncRNAs and develop a risk model for ccRCC.
By employing data from The Cancer Genome Atlas, we were able to identify prognostically significant migrasome-related lncRNAs through co-expression analysis, Cox regression, and least absolute shrinkage and selection operator (LASSO) regression. Prognostic models were developed and validated using these lncRNAs, and a nomogram combining the risk score with clinical features was constructed. Furthermore, our analyses encompassed gene set enrichment, immune infiltration, mutational burden, and drug sensitivity.
A prognostic model incorporating 13 lncRNAs effectively stratified patients into distinct risk categories, with the high-risk cohort demonstrating markedly inferior survival rates. The prognostic accuracy was validated through multiple analyses. Gene enrichment analysis revealed a correlation between these lncRNAs and tumor development and immune pathways. High-risk patients exhibited increased immunosuppressive cell infiltration, oncogenic mutations, and potential for immune escape. Furthermore, they demonstrated a lack of response to immunotherapy and exhibited differential responses to antineoplastic agents when compared to low-risk patients. We propose a prognostic model for ccRCC based on migrasome-related lncRNAs, providing new insights into disease progression and potential individualized treatment strategies.
Our study proposes a prognostic model for ccRCC based on migrasome-related lncRNAs, providing new insights into disease progression and potential individualized treatment strategies.
透明细胞肾细胞癌（ccRCC）是最常见且侵袭性最强的肾脏恶性肿瘤。迁移小体是新发现的参与细胞间通讯的细胞器，长链非编码RNA（lncRNA）是癌症进展的新兴调节因子。然而，迁移小体相关lncRNA在ccRCC预后和免疫反应中的作用仍不清楚。本研究旨在探讨迁移小体相关lncRNA的价值，并建立ccRCC的风险模型。
通过利用癌症基因组图谱的数据，我们能够通过共表达分析、Cox回归和最小绝对收缩和选择算子（LASSO）回归来识别与预后相关的迁移小体相关lncRNA。使用这些lncRNA建立并验证了预后模型，并构建了一个将风险评分与临床特征相结合的列线图。此外，我们的分析包括基因集富集、免疫浸润、突变负担和药物敏感性。
一个包含13种lncRNA的预后模型有效地将患者分为不同的风险类别，高风险队列的生存率明显较低。通过多种分析验证了预后准确性。基因富集分析揭示了这些lncRNA与肿瘤发展和免疫途径之间的相关性。高风险患者表现出免疫抑制细胞浸润增加、致癌突变和免疫逃逸的可能性。此外，与低风险患者相比，他们对免疫治疗缺乏反应，对抗肿瘤药物表现出不同的反应。我们提出了一种基于迁移小体相关lncRNA的ccRCC预后模型，为疾病进展和潜在的个体化治疗策略提供了新的见解。
我们的研究提出了一种基于迁移小体相关lncRNA的ccRCC预后模型，为疾病进展和潜在的个体化治疗策略提供了新的见解。
